Table 2.
Pembrolizumab group (n = 49) | Bevacizumab group (n = 53) | P-value | |
---|---|---|---|
Best overall response, n (%) | |||
CR | 0 | 0 | |
PR | 18 (36.7) | 23 (43.4) | |
SD | 26 (53.1) | 26 (49.1) | |
PD | 4 (8.2) | 3 (5.7) | |
No assessment | 1 (2.0) | 1 (1.9) | |
ORR (95%CI) | 36.7% (23.8% to 51.2%) | 43.4% (30.1% to 57.7%) | 0.548 |
DCR (95%CI) | 89.8% (77.0% to 96.2%) | 92.5% (80.9% to 97.6%) | 0.735 |
CR, complete response; PR, partial response; SD stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.